KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Interest & Investment Income (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Interest & Investment Income for 11 consecutive years, with $449337.0 as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 47.3% to $449337.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, down 49.23% year-over-year, with the annual reading at $2.4 million for FY2025, 49.23% down from the prior year.
  • Interest & Investment Income hit $449337.0 in Q4 2025 for Inovio Pharmaceuticals, down from $552108.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $1.9 million in Q3 2023 to a low of $449337.0 in Q4 2025.
  • Historically, Interest & Investment Income has averaged $1.1 million across 3 years, with a median of $979672.5 in 2024.
  • Biggest five-year swings in Interest & Investment Income: plummeted 42.91% in 2024 and later crashed 53.29% in 2025.
  • Year by year, Interest & Investment Income stood at $1.8 million in 2023, then crashed by 53.13% to $852587.0 in 2024, then crashed by 47.3% to $449337.0 in 2025.
  • Business Quant data shows Interest & Investment Income for INO at $449337.0 in Q4 2025, $552108.0 in Q3 2025, and $610638.0 in Q2 2025.